Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israeli Medical Technology Company Listed on Nasdaq After Merger
Error: Contact form not found.
by Lilach Baumer / CTech
A view of the exterior of the Nasdaq market site in Times Square on Tuesday, in New York City on April 25, 2017. Photo: REUTERS/Shannon Stapleton.
CTech – Jerusalem-based immunotherapy company Enlivex Therapeutics has raised $5.36 million in a private offering, pricing 437,733 shares at $12.25 per share, the company announced Tuesday. The financing was led by existing investors KIP Global Pharma Private Equity Fund, an affiliate of Seoul-headquartered venture firm Korea Investment Partners, and Jerusalem-based biotechnology company HBL-Hadasit Bio Holdings.
Enlivex completed on Tuesday its merger with Tel Aviv-headquartered Bioblast Pharma, a Nasdaq-listed clinical-stage company developing treatments for rare genetic diseases. Following the reversed merger, Enlivex became a subsidiary of Bioblast, which renamed as Enlivex Therapeutics. The merged entity listed on Nasdaq under the ticker “ENLV.”
Founded in 2005, clinical-stage Enlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post-bone marrow transplant complication.
